State Key Laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China.
State Key Laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510006, China.
Pharmacol Res. 2018 Nov;137:76-88. doi: 10.1016/j.phrs.2018.09.011. Epub 2018 Sep 15.
T lymphocytes produced by the thymus are essential mediators of immunity. Accelerated thymic atrophy appears in the patients with administration of glucocorticoids (GCs) which are commonly-used drugs to treat autoimmune and infectious diseases, leading to dysregulation of immunity with manifestation of progressive diminution of new T cell production. However, there is no ideal method to overcome such side effects of GCs. In the current study, we proposed a composition of dexamethasone (DEX) and dihydromyricetin (DMY) derived from a medicinal plant, which could protect from DEX-induced thymus damage and simultaneously enhance the anti-inflammatory effect of DEX. In the current study, we found that DEX-damaged thymic cellularity and architecture, reduced thymocyte numbers, induced thymocyte apoptosis and dropped CD4+ and CD8+ double positive T cell numbers in thymus which was effectively improved by co-treatment with DMY. Quantification of signal joint TCR delta excision circles (TRECs) and Vβ TCR spectratyping analysis were employed to determine the thymus function with indicated treatments. The results showed that DEX-impaired thymus output and decreased TCR cell diversity which was ameliorated by co-treatment with DMY. iTRAQ 2D LC-MS/MS was applied to analyze the proteomic profiling of thymus of mice treated with or without indicated agents, followed by informatics analysis to identify the correlated signaling pathway. After validated by Western blotting and Real-time PCR, we found that PPARγ-associated fatty acid metabolism was increased in the thymic tissues of the animals treated with DMY plus DEX than the animals treated with DEX alone. The agonist and antagonist of PPARγ were further employed to verify the role of PPARγ in the present study. Furthermore, DMY demonstrated a synergistic effect with co-administration of DEX on suppressing inflammation in vivo. Collectively, DMY relieved thymus function damaged by DEX via regulation of PPARγ-associated fatty acid metabolism. Our findings may provide a new strategy on protection of thymus from damage caused by GCs by using appropriate adjuvant natural agents through up-regulation of PPARγ-associated fatty acid metabolism.
胸腺产生的 T 淋巴细胞是免疫的重要介质。糖皮质激素(GCs)是治疗自身免疫和感染性疾病的常用药物,其在患者体内的加速应用会导致胸腺萎缩,从而导致免疫失调,表现为新 T 细胞生成逐渐减少。然而,目前尚无理想的方法来克服 GCs 的这种副作用。在本研究中,我们提出了一种源自药用植物的地塞米松(DEX)和二氢杨梅素(DMY)的组合物,该组合物可防止 DEX 诱导的胸腺损伤,并同时增强 DEX 的抗炎作用。在本研究中,我们发现 DEX 损害了胸腺细胞的数量和结构,减少了胸腺细胞的数量,诱导了胸腺细胞凋亡,并降低了胸腺中 CD4+和 CD8+双阳性 T 细胞的数量,而 DMY 的共同治疗可有效改善这种情况。通过定量测定信号接头 TCR δ 切除环(TRECs)和 Vβ TCR 谱型分析,用指示处理确定胸腺功能。结果表明,DEX 损害了胸腺输出并降低了 TCR 细胞多样性,而 DMY 的共同治疗可改善这种情况。采用 iTRAQ 2D LC-MS/MS 分析了用或不用指示剂处理的小鼠胸腺的蛋白质组谱,然后进行信息学分析以鉴定相关的信号通路。通过 Western blot 和 Real-time PCR 验证后,我们发现,与单独用 DEX 处理的动物相比,用 DMY 加 DEX 处理的动物的胸腺组织中与 PPARγ 相关的脂肪酸代谢增加。进一步使用 PPARγ 的激动剂和拮抗剂验证了 PPARγ 在本研究中的作用。此外,DMY 与 DEX 联合使用在体内具有协同抑制炎症的作用。总之,DMY 通过调节与 PPARγ 相关的脂肪酸代谢来缓解 DEX 引起的胸腺功能障碍。我们的发现可能通过上调与 PPARγ 相关的脂肪酸代谢,为使用适当的佐剂天然药物保护 GC 引起的胸腺损伤提供了一种新策略。